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Available online 1 August 2016Cardiac rehabilitation (CR) improves cardiac function and exercise capacity in patients with cardiovascular
disease (CVD). Simpler techniques are needed for use by physicians in the examination room to assess the
usefulness of CR.We enrolled 46 consecutive CVD patients in a CR program (CR group) and prospectively follow-
ed them for 3 months. We compared them to 18 age-, gender- and body mass index-matched CVD patients
without CR (non-CR group). Various parameters were measured at baseline and after 3 months using 3 simple
non-invasive tests: severity of atherosclerosis [arterial velocity pulse index and arterial pressure volume index
(API)] were determined using PASESA®, an autonomic nerve total activity amount index and a coefﬁcient of
variation of the R–R interval (CVRR) were determined using eHEART®, and peripheral resistance index, pressure
rate product, stroke volume and cardiac index were determined using nico®]. There were no signiﬁcant
differences in patient characteristics including percentages (%) of ischemic heart disease and heart failure
between the non-CR and CR groups. Systolic blood pressure (SBP), diastolic BP, heart rate and API at baseline
signiﬁcantly decreased and CVRR at baseline signiﬁcantly increased after 3 months in the CR group, but not in
the non-CR group. In addition, ΔAPI (Δ= the value after 3 months minus the value at baseline) was positively
associated with ΔSBP in the CR group. In conclusion, CR signiﬁcantly decreased BP and improved
atherosclerosis and sympathetic nerve activity. These ﬁndings suggest that simple non-invasive tests may be
useful for assessing the effects of CR.
© 2016 TheAuthors. Published by Elsevier Ireland Ltd. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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A coefﬁcient of variation of the R–R interval1. Introduction
Comprehensive cardiac rehabilitation (CR) has been developed in an
attempt to improve the quality of life and prognosis, in addition to
cardiac function and exercise capacity, in patients with cardiovascular
disease (CVD) [1–3]. Improvements in hospitalization and health-
related quality of life with exercise-based CR appear to be consistent
across patients regardless of the characteristics of the CR program and
CR may reduce mortality in the long term [4]. The effectiveness of CR
should be thoroughly assessed.
Non-invasive assessments, including pulse wave velocity (PWV) [5],
carotid intima-media thickness [6], ﬂow-mediated vasodilatation [7]
and augmentation index [8] can be used to detect atrial stiffness and, Fukuoka University School of
.
and Ltd. This is an open access articleassess CV risks. Although these assessments are clinically and
experimentally acceptable, they take time and present some technical
difﬁculties. Thus, simpler techniques are needed for use by physicians
in the examination room to assess the usefulness of CR. Three easy-to-
use devices, PASESA® [9], nico PS-501® [10,11] and eHEART® [12],
are currently available for clinical use in Japan. Komine et al. recently
developed a simple and non-invasive method for evaluating arterial
stiffness using oscillometric measurements of BP (PASESA® AVE-1500,
Shisei Datum, Tokyo, Japan) [9]. We recently performed synchronal
measurement using a nico PS-501® (Parama-Tech, Fukuoka, Japan)
and found that a relative difference in blood pressure (BP) between
arms may be associated with CVD [10]. The use of a PS-501® satisﬁes
the international standards for a Korotkoff sound-measuring device
[11]. In addition, ambulatory electrocardiographic (ECG) examination
using eHEART® (Parama-Tech, Fukuoka, Japan) offers a novel, rapid,
and simple method for measuring parameters of heart rate variability
(HRV), such as the coefﬁcient of variation of the R–R interval (CVRR),under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics at baseline in the non-CR and CR groups.
Non-CR group (n = 18) CR group (n = 46)
Age, y. 66 ± 12 69 ± 11
Gender (male), n (%) 9(50) 27(59)
BMI, kg/m2 23.9 ± 3.5 24.1 ± 3.1
HTN, % 12(67) 26(57)
DM, % 3(17) 9(20)
DL, % 9(50) 30(65)
CVD
IHD, % 5(28) 17(37)
Heart failure, % 8(44) 18(39)
PAD, % 0(0) 5(11)
Others, % 5(28) 6(13)
NYHA Classiﬁcation
I/II/III/IV, n (%) 38(83)/7(15)/1(2)/0(0) 15(83)/3(17)/0(0)/0(0)
LVEF, % 59 ± 15 64 ± 11
Medication
ARB/ACE-I, % 10(56) 34(74)
Diuretic, % 7(39) 13(28)
β-blocker, % 8(44) 24(52
CCB, % 12(67) 18(39)⁎
BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia; CVD,
cardiovascular disease; IHD, ischemic heart disease; PAD, peripheral arterial disease;
NYHA, NewYorkHeart Association; LVEF, left ventricular ejection fraction; ARB/ACE-I, an-
giotensin II receptor blocker (ARB)/angiotensin converting enzyme inhibitor; CCB, calcium
channel blocker.
⁎ p b 0.05 vs. Non-CR group.
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HF), all within 5 min [12].
In this study, we hypothesized that comprehensive CR could
improve HRV, the difference in BP between arms and arterial stiffness.
Therefore, we assessed the effectiveness of CR using the 3 above-
mentioned devices in patients with CVD.
2. Methods
2.1. Study population and protocol
We enrolled 46 consecutive CVD outpatients into a CR program (CR
group) and prospectively followed them for 3 months. We compared
them to 18 age-, gender- and body mass index (BMI)-matched CVD
patients without CR (non-CR group, standard pharmacological care
alone). This study was conducted in accordance with the Declaration
of Helsinki, approved by the Independent Review Board (IRB) of Fukuo-
kaUniversity Hospital (Fukuoka University Hospital IRB: #14-3-07) and
registered under UMIN000016668. All subjects gave their written
informed consent to participate.
2.2. Exercise protocol
The CR group participated in a supervised exercise training program
at the hospital's gym at least 6 times a month for 3 months. Exercise
intensity was chosen at the 50% of peak VO2 according to cardio
pulmonary exercise test (CPX) or Borg's scale 11–13 during exercise.
Each session lasted about 1 h, beginning with a warm-up exercise for
10 min, followed by 30 min of cycling or walking at the indicated
exercise intensity and 20 min of cooling down and stretching. BP and
HRwere measured at rest and at the end of exercise, and an electrocar-
diogram [Central Monitor (DS-5700) Fukuda Denshi Co. Ltd., Tokyo,
Japan] and Borg's scale were recorded during exercise. All patients
were routinely screened before each exercise session, such as by
symptoms, heart rate and rhythm, ECG, BP and medication regimen.
The following conditions had to be managed during exercise: angina,
dysrhythmia, hypotension, hypertension (HTN), dyspnea, decreased
exercise tolerance and cardiac or respiratory arrest.
2.3. Data collection
Patient characteristics includingmedications were assessed at base-
line. Coronary risk factors included age, gender, bodymass index (BMI),
HTN, dyslipidemia (DL) and diabetes mellitus (DM). Patients who had a
current systolic BP (SBP)/diastolic BP (DBP) ≥140/90 mmHg or who
were receiving antihypertensive therapy were considered to have
HTN. DM was deﬁned using the Japan Diabetes Society Criteria or
if the patient was being treated with an oral hypoglycemic agent or
insulin. Patients with low-density lipoprotein cholesterol ≥ 140 mg/dl,
triglyceride ≥ 150 mg/dl, and/or high-density lipoprotein
cholesterol b 40 mg/dl, or who were receiving lipid-lowering therapy,
were considered to have DL. Ischemic heart disease (IHD) was deﬁned
as lumen diameter stenosis N 50% in at least 1 major coronary artery as
determined by coronary angiography and as diagnosed by old
myocardial infarction. Heart failure was assumed based on the medical
history, including medications and cardiac function. Medications
includedβ-blocker, calcium channel blocker (CCB), angiotensin II recep-
tor blocker (ARB)/angiotensin converting enzyme inhibitor (ACE-I) and
diuretic. Various parameters were obtained using PASESA® [9], nico PS-
501® [10,11] and eHEART® [12] at baseline and after 3 months.
2.4. CPX
Patients underwent symptom-limited CPX using a cycle ergometer
with respiratory gas exchange analysis at baseline. The testing consisted
of an initial 2 min of rest, 1 min of warm-up at 0 W, and full exerciseunder a ramp protocol with increments of 10W/min. Expired gas anal-
ysis was performed throughout testing on a breath-by-breath basis, and
VE, VO2, and VCO2 data were collected.
2.5. Measurements of parameters of arterial stiffness using PASESA®
Wewrapped a cuff around the left upper arm of sitting patients and
measured the brachial BP oscillometrically using PASESA® after at least
5 min of rest [9]. Arterial stiffness [arterial velocity pulse index (AVI)
and atrial pressure volume index (API)], SBP, DBP and HR were
collected.
2.6. Evaluation of various hemodynamic parameters using nico PS-501®
We wrapped cuffs around both the right and left upper arms of
sitting patients after at least 5 min of rest. Bilateral brachial SBP, DBP,
pressure rate product (PRP), cardiac index (CI), total peripheral resis-
tance index (TPRI) and pulse wave to Korotkoff sound systolic time
(TP-KS) were analyzed by a nico PS-501® [10,11]. We calculated abso-
lute (|rt. BP− lt. BP|) and relative (rt. BP− lt. BP) differences in SBP and
DBP between arms.
2.7. Measurement of HRV using eHEART®
Beat-to-beat HR data in the supine positions were continuously re-
corded for 5 min using eHEART® after at least 5 min of rest. We evalu-
ated parameters of HRV, such as CVRR, HF, LF and LF/HF [12]. The
ﬂuctuations of R–R intervals were integrated on the HF band (0.15–
0.40 Hz) and the LF band (0.05–0.15 Hz). HRV was expressed as the
power of the LF and HF components and the LF/HF power ratio.
2.8. Statistics
Statistical analysis was performed using the Stat View statistical
software package (Stat View 5; SAS Institute INC., Cary, NC). Data are
expressed as the mean ± standard deviation or number (%). The
signiﬁcance of differences was evaluated using a Wilcoxon signed-
rank test or Student's t-test for continuous variables and the χ2 test
for categorical variables. A value of p b 0.05 was considered signiﬁcant.
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Fig. 1. BP (A), HR (B), AVI (C) and API (D) obtained using PASESA® in the non-CR and CR
groups. SBP, systolic blood pressure; DBP, diastolic BP; HR, heart rate; AVI, arterial velocity
pulse index; API, atrial pressure volume index. Black and gray lines indicate the CR and
non-CR groups, respectively. **p b 0.01, *p b 0.05 vs. at baseline.
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3.1. Patient characteristics at baseline in the non-CR and CR groups
Table 1 shows patient characteristics at baseline in the non-CR and
CR groups. In the CR group, the percentages (%) of male, HTN, DM, DL,
IHD and heart failure were 59%, 57%, 20%, 65%, 37% and 39%, respective-
ly, and there were no signiﬁcant differences in patient characteristics
except for % CCB between the groups. % CCB in the CR group was signif-
icantly lower than that in the non-CR group. In the CR group at baseline,
peak VO2 and anaerobic threshold were 14.6 ± 4.0 ml/kg/min and
39.5 ± 9.9 W (3.4 ± 0.9 Mets), respectively.
3.2. Determination of various parameters including arterial stiffness using
PASESA® in the non-CR and CR groups
There were no signiﬁcant differences in parameters using PASESA®
at baseline between the non-CR and CR groups, as shown in Fig. 1. SBP,
DBP, HR and API at baseline in the CR group, but not in the non-CR
group, were signiﬁcantly reduced compared to those after 3 months.Table 2
Evaluation of various hemodynamic parameters using nico PS-501® in the non-CR and CR gro
Non-CR group (n = 18)
Baseline 3 mont
SBP absolute, mmHg 2.9 ± 4.1 3.1 ± 4
Relative, mmHg 1.8 ± 4.7 0.4 ± 5
DBP absolute, mmHg 6.4 ± 5.4 1.6 ± 2
Relative, mmHg 4.6 ± 7.1 1.0 ± 2
PRP, bpm ∗mmHg 9941 ± 2988 10,366
TPRI, mmHg/l/min 1547 ± 322 1416 ±
CI, l/min/m2 3.3 ± 0.6 3.5 ± 0
TP-KS, msec 182 ± 75 187 ±
SBP, systolic blood pressure; DBP, diastolic blood pressure; PRP, pressure rate product; TPRI, tot
tolic time.
⁎ p b 0.05 vs. at baseline in the non-CR group.3.3. Evaluation of various hemodynamic parameters using nico PS-501® in
the non-CR and CR groups
There were no signiﬁcant differences in parameters obtained using
nico PS-501® at baseline between the non-CR and CR groups except
for the relative difference in DBP between arms, as shown in Table 2. Al-
though the relative difference inDBPbetween arms at baseline in theCR
group was signiﬁcantly lower than that in the non-CR group, there was
no difference in the relative difference in DBP between arms after
3 months between the groups. The absolute difference in DBP between
arms after 3 months in the non-CR group was signiﬁcantly reduced
compared to that at baseline. There were no signiﬁcant changes in
PRP, CI, TPRI or TP-KS between baseline and after 3 months in both
groups.
3.4. Measurement of HRV using eHEART® in the non-CR and CR groups
Fig. 2 shows the parameters of HRV. Therewere no signiﬁcant differ-
ences in parameters obtained using eHEART® at baseline between the
non-CR and CR groups. In addition, there were no signiﬁcant changes
in LF, HF or LF/HF in both groups. Interestingly, CVRR after 3 months
was signiﬁcantly higher than that at baseline in the CR group.
3.5. Association betweenΔAPI orΔCVRR andΔSBP orΔDBP in the CR group
(Δ= the value after 3 months minus the value at baseline)
Fig. 3 shows the associations betweenΔSBP orΔDBP andΔAPI in the
CR group. ΔAPI was positively correlated with ΔSBP, but not ΔDBP.
There were no associations between ΔCVRR and either ΔSBP
(r =−0.129, p = 0.423) or ΔDBP (r =−0.044, p = 0.784).
4. Discussion
In this prospective study, we assessed the effectiveness of a CR pro-
gram using 3 simple, non-invasive devices (PASESA®, nico PS-501®,
eHEART®). First, using PASESA®, we found that SBP, DBP, PR and API
at baseline were signiﬁcantly decreased after 3 months in the CR
group. In addition, ΔAPI was positively correlated with ΔSBP, but not
ΔDBP. Second, based on the results obtained with eHEART®, CVRR in
the CR group was signiﬁcantly increased. Thus, simple non-invasive
tests may be useful for assessing the effects of CR.
Based on the results obtained with PASESA®, CR produced
signiﬁcant reductions of SBP, DBP, PR and API after 3 months. This is
reasonable because it is now well-recognized that exercise training in
patients with chronic heart failure and HTN reduces BP [13,14]. More-
over, exercise training is also recommended to lower BP in patients
with heart failure [13]. HR reduction may be due to the suppression of
sympathetic nerve activity [15]. According to the Framingham Study,
HR may be an independent risk factor for CV death in patients with
HTN [16]. An increase of 5 bpm in the morning HR measurement wasups.
CR group (n = 46)
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Fig. 2. LF (A), HF (B), LF/HF (C) and CVRR (D) obtained using eHEART® in the non-CR and
CR groups. LF, low-frequency; HF, high-frequency; LF/HF, the ratio of LF to HF; CVRR, the
coefﬁcient of variation of the R–R interval. Black and gray lines indicate the CR and non-
CR groups, respectively. *p b 0.05 vs. at baseline.
66 T. Ueda et al. / IJC Heart & Vasculature 12 (2016) 63–67associated with a 17% increase in the risk of CVmortality [17]. Thus, HR
reduction may be one of the beneﬁts of CR. In addition, a reduction of
API, which reﬂects brachial arterial stiffness [9], was observed in the
CR group. Since ΔAPI was positively correlated with ΔSBP, a reduction
of SBP by CR may improve arterial stiffness. Many previous reports
have indicated that brachial-ankle PWV (baPWV) is an important pa-
rameter in the progression of atherosclerotic CVD [18–20], and API has
been shown to be related to baPWV, carotid-femoral PWV and carotid
arterial compliance [9]. Since PASESA® is as easy to use as the physician
simply measuring BP in the arm, it should be quite useful for assessing
the effects of CR.
CVRR, an index of parasympathetic nervous activity, in the CR group,
as assessed by eHEART®, was signiﬁcantly improved in this study. We
previously reported that LF/HF as assessed by eHEART®, in addition to
HTN and DL, might predict the presence of CVD [12]. HRV reﬂects
cardiac sympathetic and parasympathetic modulation [21], and can
provide information on the progression of focal CV atherosclerosis-50 -40 -30 -20 -10 0 10 20 30
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Fig. 3. Association between ΔAPI and ΔSBP or ΔDBP in the CR group (Δ= the value after
3 months minus the value at baseline).[22]. A marked reduction of HRV is found in patients with heart failure
[23]. Interestingly, Waon therapy has been shown to improve cardiac
function and autonomic nervous activity by increasing parasympathetic
and decreasing sympathetic nervous activity in patients with heart fail-
ure [24]. In the present study,we also conﬁrmed that CR improved para-
sympathetic modulation, and that eHEART® was useful for assessing
this change.
Although a nico PS-501® can be used to perform bilateral BP
measurements with a synchronal method, the differences in BP
between arms showed a wide variation among patients and we did
not identify any clinically signiﬁcant changes in this study. In addition,
CR did not induce beneﬁcial effects in PRP, CI, TPRI or TP-KS.
The present study has several limitations. First, this study was at a
single center and had a relatively small sample size. Second, we did
not directly conﬁrm the improvements in atrial stiffness and sympa-
thetic nerve activity induced byCR. Third, thepatients received different
doses and kinds of medications. We analyzed whether there are
signiﬁcant differences in ΔSBP, ΔDBP, ΔHR, ΔAPI and ΔCVRR between
CR patients with and without each medication (ARB/ACE-I, diuretic, β-
blocker or CCB treatment). No signiﬁcant differences were observed in
ΔSBP, ΔDBP, ΔHR and ΔCVRR between the patients with and without
each medication (data not shown). Since ΔAPI in patients with β-
blocker treatment signiﬁcantly decreased compared to those without
β-blocker (p = 0.003), a multivariate analysis was performed using a
logistic regression analysis for independent variables [mediations
(ARB/ACE-I, diuretic, β-blocker or CCB), HTN, left ventricular ejection
fraction at baseline in addition to age, gender and BMI] that may be
related to ΔAPI. Improvement of API was not independently associated
with any variables including β-blocker (p = 0.091). Forth, we should
measure the levels of norepinephrine, epinephrine and dopamine in
blood to analyze the mechanisms of beneﬁcial effects of CR. Therefore,
a large controlled randomized study should be performed to conﬁrm
that CR improves SBP, DBP, HR, API and CVRR that can be determined
non-invasively.
In conclusion, CR signiﬁcantly decreased BP and improved athero-
sclerosis and sympathetic nerve activity. Simple non-invasive devices
may be useful for assessing the effectiveness of CR.Conﬂict(s) of interest/disclosure(s)
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